Sarah Hollis Winkler Sells 737 Shares of GenMark Diagnostics, Inc (NASDAQ:GNMK) Stock

GenMark Diagnostics, Inc (NASDAQ:GNMK) VP Sarah Hollis Winkler sold 737 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $17.30, for a total transaction of $12,750.10. Following the sale, the vice president now owns 126,274 shares in the company, valued at approximately $2,184,540.20. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

GenMark Diagnostics stock opened at $17.86 on Friday. The company has a current ratio of 3.15, a quick ratio of 2.78 and a debt-to-equity ratio of 5.52. GenMark Diagnostics, Inc has a 1 year low of $3.36 and a 1 year high of $19.83. The firm’s 50 day moving average price is $15.33 and its 200-day moving average price is $8.98.

GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Monday, May 4th. The medical equipment provider reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. GenMark Diagnostics had a negative net margin of 40.18% and a negative return on equity of 310.58%. The firm had revenue of $38.74 million during the quarter, compared to analyst estimates of $38.70 million. On average, equities analysts forecast that GenMark Diagnostics, Inc will post -0.42 EPS for the current year.

GNMK has been the topic of a number of recent analyst reports. Cowen raised their target price on shares of GenMark Diagnostics from $10.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. BidaskClub upgraded shares of GenMark Diagnostics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 22nd. Zacks Investment Research cut shares of GenMark Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 28th. Needham & Company LLC lifted their price objective on shares of GenMark Diagnostics from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, ValuEngine cut shares of GenMark Diagnostics from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Four analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $14.75.

Hedge funds have recently bought and sold shares of the stock. Advisor Group Holdings Inc. purchased a new position in shares of GenMark Diagnostics in the first quarter valued at $36,000. Aperio Group LLC purchased a new position in shares of GenMark Diagnostics in the first quarter valued at $42,000. Nisa Investment Advisors LLC grew its holdings in shares of GenMark Diagnostics by 33.3% in the second quarter. Nisa Investment Advisors LLC now owns 3,200 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 800 shares in the last quarter. Amalgamated Bank purchased a new position in shares of GenMark Diagnostics in the fourth quarter valued at $50,000. Finally, Arizona State Retirement System purchased a new position in shares of GenMark Diagnostics in the first quarter valued at $51,000. 83.88% of the stock is owned by hedge funds and other institutional investors.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

See Also: What is a stock portfolio tracker?

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.